TY - JOUR T1 - Iatrogenic Cushing’s syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies JF - Clinical Medicine JO - Clin Med SP - 412 LP - 418 DO - 10.7861/clinmedicine.16-5-412 VL - 16 IS - 5 AU - Emilie R Elliot AU - Aikaterini Theodoraki AU - Lakshmi R Jain AU - Neal J Marshall AU - Marta Boffito AU - Stephanie E Baldeweg AU - Laura J Waters Y1 - 2016/10/01 UR - http://www.rcpjournals.org/content/16/5/412.abstract N2 - Ritonavir and cobicistat, used as pharmacokinetic enhancers in combination with some antiretrovirals (ARVs) for the treatment of HIV, are potent inhibitors of the CYP3A4 isoenzyme. Most glucocorticoids are metabolised via the CYP3A4 pathway and iatrogenic Cushing’s syndrome (ICS), with possible secondary adrenal insufficiency (SAI), is a recognised complication following co-administration with ritonavir or cobicistat. A structured approach for identifying and managing potentially affected individuals has not been established.We systematically identified patients with ICS/SAI and found substantial heterogeneity in clinical practice across three large London HIV centres. While this significant drug interaction and its complications are now well-recognised, it is apparent that there is no standardised approach to management or guidance for the general physician. Here we describe the management of ICS/SAI in our current practice, review the available evidence and suggest practice recommendations. ER -